Insider trades › OrbiMed Genesis GP LLC
OrbiMed Genesis GP LLC
A corporate insider: an officer, director or owner of more than 10% of a company. Insiders report their trades to the SEC on Form 4The form insiders use to report each purchase or sale of their company's stock. It is due within two business days of the trade. · Last filing Sep 30, 2026
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, list OrbiMed Genesis GP LLC's open-market buys and sells across companies in the last two years, with the Form 4 links.
Using 13F.ai, how did the stocks OrbiMed Genesis GP LLC bought perform after the purchase compared with the S&P 500?
Using 13F.ai, are other insiders at the same companies buying or selling at the same time as OrbiMed Genesis GP LLC?
Connect your AI · Plans and the 7-day free trial (card required)
Buying and selling by quarter
Dollars bought and sold on the open market over the last two years.
Bought Sold
By trade date, using the shares and price reported for each trade. Stock grants, option exercises and shares withheld for tax are left out.
Roles
The companies where this person reports as an insider, and their position at each, most recent first.
| ADRX ADARx Pharmaceuticals, Inc. | Director, 10% owner | Sep 30, 2026 |
| ETRA Electra Therapeutics, Inc. | Director | Sep 18, 2026 |
| BRVE Braveheart Bio, Inc. | Director, 10% owner | Aug 11, 2026 |
| STTK Shattuck Labs, Inc. | Director | Jun 9, 2026 |
| PRLD Prelude Therapeutics Incorporated | Director, 10% owner | Apr 23, 2026 |
| IMA ImageneBio, Inc. | Director | Apr 16, 2026 |
| KROS Keros Therapeutics, Inc. | Director | Dec 18, 2025 |
| EWTX Edgewise Therapeutics, Inc. | Director, 10% owner | Apr 4, 2025 |
| MBX MBX Biosciences, Inc. | Director, 10% owner | Feb 19, 2025 |
Roles come from the filings themselves and can change over time.
Latest open-market trades
Purchases and sales at every company, most recent filing first.
| How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss. | Filing | ||||||
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Buy | 61,516 | $17.00 | $1.0M | -27.8% | Form 4 ↗ |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Buy | 300,249 | $17.00 | $5.1M | -27.8% | Form 4 ↗ |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | Buy | 588,235 | $17.00 | $10.0M | -27.8% | Form 4 ↗ |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc. | Buy | 1.67M | $18.00 | $30.0M | -32.2% | Form 4 ↗ |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc. | Buy | 273,333 | $18.00 | $4.9M | -32.2% | Form 4 ↗ |
| Apr 21, 2026 | PRLD Prelude Therapeutics Incorporated | Buy | 1.13M | $4.44 | $5.0M | -32.5% | Form 4 ↗ |
| Apr 21, 2026 | PRLD Prelude Therapeutics Incorporated | Buy | 1.69M | $4.44 | $7.5M | -32.5% | Form 4 ↗ |
| Apr 3, 2025 | EWTX Edgewise Therapeutics, Inc. | Buy | 372,578 | $20.13 | $7.5M | +197.7% | Form 4 ↗ |
| Apr 3, 2025 | EWTX Edgewise Therapeutics, Inc. | Buy | 124,193 | $20.13 | $2.5M | +197.7% | Form 4 ↗ |
| Feb 18, 2025 | MBX MBX Biosciences, Inc. | Buy | 49,070 | $10.84 | $531.9K | +389.8% | Form 4 ↗ |
| Feb 18, 2025 | MBX MBX Biosciences, Inc. | Buy | 94,100 | $10.84 | $1.0M | +389.8% | Form 4 ↗ |
| Feb 14, 2025 | MBX MBX Biosciences, Inc. | Buy | 17,962 | $9.90 | $177.8K | +413.6% | Form 4 ↗ |
| Feb 14, 2025 | MBX MBX Biosciences, Inc. | Buy | 29,540 | $9.85 | $291.0K | +413.6% | Form 4 ↗ |
Each row links to its Form 4. Since trade compares the stock’s move from the close on the trade date (or the next trading day) to its latest close with the S&P 500 over the same days, adjusted for splits and excluding dividends. It describes the stock, not what the trader made: we don’t know their purchase price, position size or later sales. A dash means the trade isn’t matched to a listed stock, or there is no closing price after it yet.
When several people report on the same filing, we list it under the first one named, so trades by someone usually listed second may be missing here. Information, not investment advice: see the disclaimer.